CY2017041I2 - Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη - Google Patents

Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Info

Publication number: CY2017041I2
Authority: CY; Cyprus
Prior art keywords: bupropion; compositions; weight loss; opioid antagonist; affecting weight
Prior art date: 2003-04-29

Application number

CY2017041C

Other languages

English (en)

Other versions

CY2017041I1 (el

Original Assignee

Orexigen Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-29

Filing date

2017-12-11

Publication date

2018-09-05

2004-04-21 Priority claimed from EP04760321A external-priority patent/EP1617832B1/en

2017-12-11 Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.

2018-09-05 Publication of CY2017041I2 publication Critical patent/CY2017041I2/el

2018-09-05 Publication of CY2017041I1 publication Critical patent/CY2017041I1/el

Links

SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title 1
229960001058 bupropion Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003401 opiate antagonist Substances 0.000 title 1
230000004580 weight loss Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CY2017041C 2003-04-29 2017-12-11 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη CY2017041I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46683803P	2003-04-29	2003-04-29
EP04760321A EP1617832B1 (en)	2003-04-29	2004-04-21	Compositions for affecting weight loss
EP07116330A EP1870096A3 (en)	2003-04-29	2004-04-21	Compositions for affecting weight loss

Publications (2)

Publication Number	Publication Date
CY2017041I2 true CY2017041I2 (el)	2018-09-05
CY2017041I1 CY2017041I1 (el)	2018-09-05

Family

ID=38719840

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20171100932T CY1119418T1 (el)	2003-04-29	2017-09-05	Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
CY2017041C CY2017041I1 (el)	2003-04-29	2017-12-11	Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20171100932T CY1119418T1 (el)	2003-04-29	2017-09-05	Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Country Status (6)

Country	Link
EP (1)	EP1870096A3 (el)
BE (1)	BE2017C064I2 (el)
CY (2)	CY1119418T1 (el)
FR (1)	FR17C1058I2 (el)
LU (1)	LUC00054I2 (el)
NL (1)	NL300918I2 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10576045B2 (en)	2011-02-16	2020-03-03	Nir Barak	Low dosage combinations of fluoxetine and reboxetine for treating obesity
WO2014120936A2 (en)	2013-01-30	2014-08-07	Pharmorx Therapeutics, Inc.	Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4217353A (en) *	1978-05-19	1980-08-12	E. I. Du Pont De Nemours And Company	Method for inducing anorexia
EP0782445B1 (en) *	1994-09-19	2002-03-13	Dupont Pharmaceuticals Company	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
ATE344668T1 (de) *	1996-05-07	2006-11-15	Pliva Istrazivanje I Razvoj D	Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
US6110973A (en) *	1998-01-29	2000-08-29	Sepracor	Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6071918A (en) *	1999-07-21	2000-06-06	Dupont Pharmaceuticals Company	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) *	1999-10-04	2002-06-11	Martin C. Hinz	Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) *	2000-01-22	2001-07-26	Albert Shulman	Methods for the treatment of substance abuse
ES2310192T3 (es) *	2000-09-18	2009-01-01	Sanos Bioscience A/S	Uso de peptidos glp-2.
US20030087896A1 (en) *	2001-08-09	2003-05-08	Hillel Glover	Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) *	2002-07-01	2004-05-27	Wong Erik Ho Fong	Method of promoting smoking cessation
US20050176746A1 (en) *	2002-05-17	2005-08-11	Frank Weber	Use of compounds that are effective as selective opiate receptor modulators
US6972291B2 (en) *	2002-07-02	2005-12-06	Bernstein Richard K	Method for reducing food intake

2004
- 2004-04-21 EP EP07116330A patent/EP1870096A3/en not_active Withdrawn
2017
- 2017-09-05 CY CY20171100932T patent/CY1119418T1/el unknown
- 2017-12-08 FR FR17C1058C patent/FR17C1058I2/fr active Active
- 2017-12-11 NL NL300918C patent/NL300918I2/nl unknown
- 2017-12-11 LU LU00054C patent/LUC00054I2/en unknown
- 2017-12-11 CY CY2017041C patent/CY2017041I1/el unknown
- 2017-12-12 BE BE2017C064C patent/BE2017C064I2/fr unknown

Also Published As

Publication number	Publication date
EP1870096A3 (en)	2011-04-20
CY1119418T1 (el)	2018-03-07
BE2017C064I2 (el)	2023-08-09
FR17C1058I2 (fr)	2019-01-11
NL300918I2 (nl)	2018-01-09
EP1870096A2 (en)	2007-12-26
NL300918I1 (nl)	2017-12-14
CY2017041I1 (el)	2018-09-05
LUC00054I1 (el)	2017-12-13
FR17C1058I1 (el)	2018-01-12
LUC00054I2 (el)	2018-02-21

Similar Documents

Publication	Publication Date	Title
CY2017027I2 (el)	2018-04-04	Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
CY2011013I1 (el)	2014-04-09	Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων
EP1701725A4 (en)	2009-07-01	PROCESS AND COMPOSITIONS
EP1663112A4 (en)	2009-08-19	INTRANASAL OPIOID COMPOSITIONS
IL171285A (en)	2016-02-29	Pharmaceuticals containing interleukin-6 antagonist and their uses
DK3494995T3 (da)	2020-03-23	Superfin formoterolformulering
IL174909A (en)	2010-11-30	Pharmaceutical compositions containing an interleukin-6 antagonist
IL176122A0 (en)	2006-10-05	Pharmaceutical compositions containing an interleukin-6 antagonist
DK1682142T3 (da)	2012-10-15	M3-muscarin-acetylcholin-receptor-antagonister
ATE354631T1 (de)	2007-03-15	Nuancierungsmittel
DE602004030727D1 (de)	2011-02-03	Insassenbeinschutzvorrichtung
ATE452121T1 (de)	2010-01-15	Casr-antagonist
ITFI20030104A1 (it)	2004-10-11	Apparecchiatura per terapie di ipertemia non distruttiva
DE602004006473D1 (de)	2007-06-28	Insassenbeinschutzvorrichtung
DE602004004278D1 (de)	2007-02-22	4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
IS8117A (is)	2005-11-07	3-Flúr-píperidín sem NMDA/NR2B mótlyf
IL178461A0 (en)	2007-02-11	Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
DE60325848D1 (de)	2009-03-05	Flammwidrige zusammensetzungen
CY2017041I2 (el)	2018-09-05	Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
DE602004016159D1 (de)	2008-10-09	Testeinrichtung
AU2002307802A8 (en)	2003-10-08	Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
DE60309128D1 (de)	2006-11-30	LSI-Testanordnung
NO20054040D0 (no)	2005-08-31	Utslagsmatte for golf
ATE556128T1 (de)	2012-05-15	Benzinzusammensetzungen
ITMI20030199A1 (it)	2004-08-07	Miscele non azeotropiche